This ADC product is comprised of an anti-TPBG monoclonal antibody (clone A1) conjugated via a hydroxyl amino PEG linker to MMAD. The MMAD is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAD binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. The encoded protein is an oncofetal antigen that is specific to trophoblast cells. In adults this protein is highly expressed in many tumor cells and is associated with poor clinical outcome in numerous cancers. Alternate splicing in the 5 UTR results in multiple transcript variants that encode the same protein.
ADC Antibody
Overview
Humanized Anti-TPBG antibody, clone # A1
Clone #
A1
Species Reactivity
Human
ADC Linker
Name
hydroxyl amino PEG linker
Description
Polyethylene glycol (PEG) is a particularly attractive as a linker for conjugation. The specific characteristics of PEG moieties relevant to pharmaceutical applications include: Water solubility; Lack of toxicity; Low immunogenicity; Well defined chain lengths and molecular weights.
ADC payload drug
Name
MMAD (monomethyl auristatin D)
Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.